Otrivin drops and spray: instructions for use, price, reviews during pregnancy. Children's Otrivin

Pharmacodynamics and pharmacokinetics

Xylometazoline is a drug belonging to the group of decongestants , which have local vasoconstrictor effectiveness, as a result of which they are widely used in ENT practice . The drug has a pronounced alpha-adrenomimetic effect . Local application of xylometazoline to the mucous membranes of the nose and nasopharynx leads to a narrowing of the blood vessels in them, as well as the elimination of hyperemia and swelling and, as a result, to the relief of nasal breathing in painful conditions that occur with nasal congestion ( rhinitis ).

Xylometazoline has a balanced pH characteristic of the nasal cavity and is quite well tolerated by patients with sensitive mucous membranes. The anticongestive effect of the drug does not prevent the discharge of nasal mucus.

Additional ingredients of the drops and spray - hypromellose and sorbitol - act as additional moisturizers, which helps reduce the symptoms of dryness and irritation of the mucous membranes observed with prolonged use of xylometazoline.

Levomenthol and eucalyptol included in the menthol and eucalyptus spray have a cooling and refreshing effect.

The use of the drug in therapeutic dosages does not cause hyperemia and does not lead to irritation of the mucous membranes. The pharmacological effectiveness of xylometazoline is noted within a few (3-5) minutes after its topical use and is observed for 12 hours.

The absorption of xylometazoline when applied topically tends to zero, and its plasma content is so small that it cannot be determined using existing analytical methods.

Otrivin Children's nasal spray for children 0.05%, 10ml

A country

Switzerland
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Xylometazoline

Description

Otrivin Children's - spray is used for respiratory diseases with symptoms of rhinitis (runny nose)*. • Helps fight nasal congestion thanks to the active ingredient - xylometazoline. • Moisturizing formula helps reduce symptoms of irritation and dryness of the nasal mucosa. • Can be used in children over 2 years of age. Relieves congestion in 2 minutes, maintaining the effect for up to 12 hours*. * Instructions for medical use, RU No. P N011649/03 dated 12/28/09

Compound

1 ml of the drug contains active ingredient: xylometazoline hydrochloride 0.5 mg. Excipients: sodium dihydrophosphate dihydrate 5 mg, sodium hydrophosphate dodecahydrate 1.7 mg, disodium edetate 0.5 mg, benzalkonium chloride 50% solution 0.1 mg (in terms of benzalkonium chloride 0.05 mg), sorbitol 70% 20 mg , hypromellose-4 thousand 5 mg, sodium chloride 4 mg, water up to 1 ml.

Product description

A transparent, colorless solution with virtually no odor.

pharmachologic effect

Pharmacological properties Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with an α-adrenomimetic effect, causing constriction of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasopharyngeal mucosa. Xylometazoline also reduces the accompanying hypersecretion of mucus and facilitates the drainage of nasal passages blocked by secretions, and thus improves nasal breathing during nasal congestion. Xylometazoline is well tolerated by patients with sensitive mucous membranes; its effect does not interfere with mucus secretion. xylometazoline has a balanced pH value characteristic of the nasal cavity. The drug contains inactive components - sorbitol and hypromellose (methylhydroxypropylcellulose), which are humectants. Thus, the moisturizing formula helps reduce the symptoms of irritation and dryness of the nasal mucosa that occur with long-term use of xylometazoline. In therapeutic concentrations, the drug does not irritate the mucous membrane and does not cause hyperemia. The effect occurs 2 minutes after application and lasts for 12 hours (for example, throughout the night). In vitro studies have shown that xylometazoline suppresses the infectious activity of human rhinovirus, which causes the common cold. When applied topically in recommended dosages, it is practically not absorbed, plasma concentrations are below the detection limit.

Indications for use

Acute respiratory diseases with symptoms of rhinitis (runny nose), acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (to reduce swelling of the nasopharyngeal mucosa). Preparing the patient for diagnostic manipulations in the nasal passages.

Contraindications

Hypersensitivity to xylometazoline and other components of the drug, arterial hypertension, tachycardia, severe atherosclerosis, glaucoma, dry rhinitis or atrophic rhinitis, hyperthyroidism, condition after transsphenoidal hypophysectomy, surgical interventions on the meninges (history), children under 2 years of age.

Carefully

Diabetes; pheochromocytoma; diseases of the cardiovascular system (including ischemic heart disease, angina pectoris); prostatic hyperplasia; with increased sensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure

Use during pregnancy and lactation

The drug should not be used during pregnancy. During lactation, the drug should be used only after a thorough assessment of the risk-benefit ratio for the mother and baby, under the supervision of a physician. Do not exceed the recommended dosage

Directions for use and doses

Intranasally. Children from 2 to 5 years: 1 injection into each nasal passage 1-3 times a day. Children from 6 to 11 years old: 1-2 injections into each nasal passage 2-3 times a day. Should not be used more than 3 times a day. The drug should be used in children under adult supervision. It is recommended to carry out the last application immediately before bedtime.

Side effect

Classification of the frequency of occurrence of adverse reactions: very often (≥ 10); often (≥1/100, From the immune system: Very rare: hypersensitivity reactions angioedema, rash, itching. From the nervous system: Often: headache. Rarely: insomnia, depression (with prolonged use in high doses). From the side sensory organs: Very rare: impaired clarity of visual perception From the cardiovascular system: Rare: palpitations, increased blood pressure Very rare: tachycardia, arrhythmia From the respiratory system: Often: irritation and/or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the mucous membrane of the nasopharynx. From the digestive system: Often: nausea. Rarely: vomiting. Local reactions: Often: burning at the site of application. If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects effects not listed in the instructions, please inform your doctor.

Overdose

Xylometazoline, when administered topically in an excessive dose or accidentally ingested, can cause severe dizziness, increased sweating, a sharp decrease in body temperature, headache, bradycardia, increased blood pressure, respiratory depression, coma and convulsions. Following an increase in blood pressure, a sharp decrease may be observed. Appropriate supportive measures should be taken if overdose is suspected, and in some cases immediate symptomatic treatment under medical supervision is indicated. These measures should include monitoring the patient for several hours. In cases of severe poisoning with cardiac arrest, resuscitation efforts should continue for at least 1 hour

Interaction with other drugs

Xylometazoline is contraindicated in patients currently receiving MAO inhibitors or who have received them within the previous 2 weeks. The simultaneous use of tri- or tetracyclic antidepressants and sympathomimetic drugs can lead to an increase in the sympathomimetic effect of xylometazoline, so this combination is recommended to be avoided.

special instructions

It is not recommended to use continuously for more than 10 days. Do not exceed recommended doses, especially in children and the elderly. Long-term (more than 10 days) or excessive use of the drug may cause a rebound effect (rhinitis medicamentosa) and/or atrophy of the nasal mucosa. Benzalkonium chloride, which is part of the drug, can cause irritation of the nasal mucosa.

Release form

Dosed nasal spray [for children], 0.05%. 10 ml of the drug in a bottle made of high-density polyethylene, equipped with a pump dispenser with a tip and a protective cap made of polyethylene. The bottle along with instructions for use is placed in a cardboard box. Secondary packaging is allowed to have a first-opening control.

Storage conditions

At a temperature not exceeding 30 C, out of the reach of children.

Best before date

3 years. Do not use after expiration date.

Indications for use

The use of Otrivin drops or spray is indicated for:

observed otitis media (in order to reduce swelling of the mucous membranes of the nasopharynx);
diagnosed acute respiratory infections occurring with manifestations of rhinitis ( runny nose );
eustachites;
acute rhinitis of allergic etiology;
allergic seasonal rhinoconjunctivitis;
sinusitis;
preparing the patient for diagnostic procedures in the nasal passages.

Contraindications

The administration of any of the pharmacological forms of Otrivin is contraindicated in the following cases:

atrophic rhinitis;
arterial hypertension;
hyperthyroidism;
tachycardia;
conditions after transsphenoidal hypophysectomy ;
severe atherosclerosis ;
surgical operations on the meninges (in history);
glaucoma;
increased personal sensitivity to drug ingredients;
under the age of 1 year (for 0.05% of drugs), up to 12 years (for 0.1% of drugs).

With extreme caution, it is possible to prescribe any of the dosage forms of Otrivin for:

pregnancy;
diabetes mellitus;
breastfeeding;
cardiovascular pathologies;
prostate adenoma;
increased sensitivity to the effects of adrenergic drugs, occurring with increased blood pressure , insomnia , arrhythmia , dizziness , tremor .

Special instructions for the use of Otrivin

The drug should not be used for more than 10 days in a row. Longer treatment with the drug may cause the opposite effect. Prescribe with caution to patients who, when using adrenergic drugs, experience strong reactions, expressed in the form of insomnia, dizziness, yeast, arrhythmias, and increased blood pressure. The recommended dose of the drug should not be exceeded, especially when treating children and the elderly. Prescribe the drug with caution to patients with cardiovascular diseases, hypertension (arterial hypertension), closed-angle glaucoma, diabetes mellitus, and thyroid diseases. Use during pregnancy and lactation. The drug is contraindicated during pregnancy due to its vasoconstrictor effect. There is no evidence of side effects of the drug in infants, during maternal treatment with the drug and breastfeeding. It is not known whether xylometazoline passes into breast milk, so women who are breastfeeding can use the drug when the expected benefit to the mother outweighs the potential risk to the baby. The drug does not affect the ability to drive vehicles or operate complex machinery when used in recommended doses.

Side effects

Local reactions from the mucous membranes (most often observed with frequent and/or prolonged use):

hypersecretion;
dryness and/or irritation;
tingling or burning sensation;
sneezing;
swelling.

Systemic reactions (most often observed with frequent and/or prolonged use):

nausea, vomiting;
blurred vision;
headache;
tachycardia;
allergic manifestations;
feeling of heartbeat;
insomnia;
arrhythmia;
dizziness;
increased blood pressure;
depressive states.

Otrivin Complex

Classification of the frequency of occurrence of adverse reactions:

Very common (≥ 1/10); often (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10000, <1/1000); very rare (<1/10000). Immune system disorders: Not known: hypersensitivity. Nervous system disorders: Common: taste disturbance, headache; Uncommon: impaired sense of smell, dizziness, tremor; Very rare: insomnia. Eye disorders: Uncommon: eye irritation, dry eyes; Frequency unknown: increased intraocular pressure, mydriasis, eye pain, photopsia, worsening of angle-closure glaucoma, impaired visual clarity, pupil dilation, halo effect (rainbow circles around the light source in the field of view). Cardiac disorders: Uncommon: palpitations, supraventricular tachycardia; Very rare: arrhythmic pulse; Frequency unknown: atrial fibrillation. Respiratory, thoracic and mediastinal disorders: Very common: nosebleeds, irritation and/or dryness of the nasopharyngeal mucosa; Common: burning sensation, tingling sensation, sneezing, nasal hypersecretion; nasal congestion (with frequent and/or long-term use of the drug), dry throat, sore throat, rhinalgia; Uncommon: nasal ulcer, sneezing, sore throat, cough, dysphonia; Rarely: runny nose; Frequency unknown: discomfort in the paranasal sinuses, laryngeal spasm, pharyngeal edema. Gastrointestinal disorders: Common: dry mouth; Uncommon: dyspepsia, nausea; Frequency unknown: difficulty swallowing. Skin and subcutaneous tissue disorders: Frequency unknown: itching, skin rash, urticaria. Renal and urinary tract disorders: Frequency unknown: difficulty urinating. General disorders and disorders at the injection site: Uncommon: discomfort, fatigue; Frequency unknown: chest discomfort, thirst. Allergic reactions: Rarely: systemic allergic reactions (anaphylactic reaction, angioedema of the tongue, lips and face, laryngospasm). If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Be sure to read the instructions for use.

Instructions for use of Otrivin

Otrivin drops, instructions for use

Before using the drops, you should thoroughly clean the nasal passages, for which it is recommended to use products in the form of a cleansing spray containing sea water , for example Otrivin Sea.

Otrivin nasal drops 0.1% are intended for the treatment of patients over 12 years of age. You can drop 2-4 drops into each nasal passage once. This instillation procedure can be performed no more than 3 times per day. The therapeutic course should not exceed 10 days.

The instructions for Otrivin for children in the form of 0.05% drops recommend their use for the treatment of children 1-12 years old, under the supervision of adults. At the age of 1-6 years, instillation of 1-2 drops per day into each nasal passage is recommended, with a duration of treatment not exceeding 7 days. At the age of 6-12 years, you can instill children's Otrivin 2-4 drops into each nasal passage 2-3 times every 24 hours. The duration of treatment should be limited to 7-10 days.

Otrivin spray, instructions for use

Just as when using drops, before using the spray it is necessary to clean the nasal passages using Otrivin Sea spray or another similar preparation containing sea water .

Patients over 12 years of age are recommended to use a 0.1% spray. One injection is made into each nasal passage, with a frequency of no more than 3 times a day. The duration of therapy should not exceed 10 days.

Spray for children 0.05% is indicated for use from 1 to 12 years old, under the supervision of adults. For children 1-6 years old, 1 injection procedure is recommended in each nasal passage, with a frequency of 1-2 times every 24 hours. Patients 6-12 years old can receive single injections into each nasal passage 2-3 times a day. It is better to limit the duration of treatment to 7 days.

Otrivin nasal drops for children 0.05% 10ml No.1

Name

Otrivin nasal children 0.05% in fl. 10ml per pack. No. 1

Description

White opalescent liquid with the smell of menthol and eucalyptus.

Main active ingredient

Xylometazoline

Release form

10 ml in a bottle made of high-density polyethylene, equipped with a pump dispenser with a tip and a protective cap made of polyethylene. The bottle along with instructions for use is placed in a cardboard pack.

Dosage

10ml

special instructions

Do not exceed the recommended dose and duration of use of the drug. Impact on the use of machinery and the ability to drive vehicles: Xylometazoline, in dosages exceeding the recommended ones, may affect the use of machinery and the ability to drive vehicles.

pharmachologic effect

The pharmacological effect occurs within a few minutes and lasts for several hours. Pharmacotherapeutic group: alpha adrenergic agonist. ATX code: R01AA07. Pharmacological properties: Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with a β-adrenomimetic effect, which manifests itself:

narrowing of the blood vessels of the mucous membrane and leads to the elimination of swelling and hyperemia of the mucous membrane of the nose and nasopharynx
facilitates nasal breathing with rhinitis
menthol and eucalyptol contained in the preparation have a cooling effect on the nasal mucosa
in therapeutic concentrations does not irritate the mucous membrane and does not cause hyperemia.

Pharmacokinetics

When applied topically, it is practically not absorbed; the concentrations in the blood plasma are so small that they cannot be determined by modern analytical methods.

Indications for use

acute respiratory diseases with symptoms of rhinitis (runny nose)

acute allergic rhinitis
hay fever
sinusitis
eustachitis
otitis media (to reduce swelling of the nasopharyngeal mucosa).
preparing the patient for diagnostic manipulations in the nasal passages.

Directions for use and doses

Intranasally. For adults and children over 6 years of age: 1 injection into each nasal passage (can be repeated if necessary); Usually 3-4 injections per day are sufficient. Duration of use - no more than 10 days in a row.

Interaction with other drugs

Incompatible with MAO inhibitors and tricyclic antidepressants.

Contraindications

Hypersensitivity to the components of the drug, arterial hypertension, tachycardia, severe atherosclerosis, glaucoma, atrophic rhinitis, hyperthyroidism, surgical interventions on the meninges (and history). Children's age - up to 6 years. Be careful with diabetes.

Compound

1 ml of solution for intranasal use contains: Active ingredient: xylometazoline hydrochloride 1 mg. Excipients: Sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, sodium chloride, benzalkonium chloride, sorbitol, disodium edetate, levomenthol (menthol), cineol (eucalyptol), Cremophor RH 40, purified water.

Overdose

Manifested by increased symptoms of side effects. Treatment is symptomatic.

Side effect

With frequent and/or prolonged use - irritation and/or dryness of the mucous membrane of the nasopharynx, burning, tingling, sneezing, hypersecretion of mucus. Rarely - swelling of the nasal mucosa, tachycardia, increased blood pressure, headache, dizziness, vomiting, insomnia, blurred vision.

Storage conditions

At a temperature not exceeding 25 °C, out of the reach of children.

Overdose

When using excessive dosages of Otrivin or using it for more than the time recommended by the instructions, side effects inherent to the drug may occur or an increase in already observed negative phenomena: increased heart rate , increased blood pressure , and occasionally confusion .

The treatment of such complications should correspond to the observed negative symptoms.

special instructions

Both Otrivin drops and spray should not be used for more than 10 days in a row. Excessive and/or prolonged use of the drug may cause the formation of stagnant reactive effects and/or atrophy of the nasal mucous membranes .

This drug should be prescribed with caution in patients who react strongly to the effects of adrenergic drugs , including manifestations of insomnia , increased blood pressure, tremor , dizziness, and cardiac arrhythmia .

Exceeding the recommended dosages of Otrivin should be avoided, especially when treating elderly patients and children.

Patients suffering from cardiovascular pathologies, diabetes mellitus , arterial hypertension, pheochromocytoma , prostate adenoma , porphyria and thyroid pathologies require careful administration of the drug.

A bottle of drops or spray is intended exclusively for use by one patient, due to the possible spread of infection.

Benzalkonium chloride included in the drug may irritate the nasal mucous membranes.

Pharmacological properties of the drug Otrivin

Xylometazoline is a sympathomimetic agent acting on α-adrenergic receptors. Otrivin causes constriction of the nasal blood vessels, reducing swelling of the nasal mucosa and paranasal sinuses and thus improves nasal breathing when the nose and paranasal sinuses are congested. The effect begins a few minutes after application and lasts up to 12 hours. The drug is well tolerated, including by patients with sensitive mucous membranes. The drug does not reduce mucociliary clearance. Nasal drops and nasal spray Otrivin have a balanced pH value within the boundaries characteristic of the nasal cavity. Thanks to moisturizing components (sorbitol, hypromellose), the drops help with dryness and irritation of the mucous membrane of the nasal passages. Spray (with menthol and eucalyptus) contains cooling aromatic substances that evaporate - menthol and eucalyptol. When applied topically, it is practically not absorbed; the concentration of xylometazoline in the blood plasma is so low that it cannot be determined by modern analytical methods.

Analogs

Level 4 ATX code matches:
Xymelin Eco

Xymelin

Nazivin

Galazolin

Lazorin

Nazivin Sensitive for children

Naphthyzin

Sanorin

Knoxprey

For the nose

Lazolvan Rino

Afrin

Rhinorus

Eucazoline Aqua

Rinazolin

Grippostad Reno

Farmazolin

Xylometazoline

Nazol Advance

Nazol Baby

Analogs of the drug in the form of drops or sprays, the main effects of which are identical to those of Otrivin:

Nazivin;
Vicks Active;
Tizin;
Nazol;
Lazorin;
Naphthyzin;
Sanorin;
Afrin;
Knoxprey;
Rint;
Operil;
Rinazolin;
Naso-Spray , etc.

Synonyms

Topical preparations with the same active ingredient:

Farmazolin;
For the nose;
Galazolin;
Grippostad Reno;
Xylohexal;
Grippocitron Rhinos;
Xinos;
Olinth;
Meralis;
Rinoxyl;
Eucabalus;
Tizin Xylo;
Sialor , etc.

For children

All 1% dosage forms of the drug can be prescribed to children only after they reach 12 years of age. The instructions for the drug allow the use of Otrivin for children aged 1-12 years only at a dose of 0.5 mg/1 ml (0.05%), under the supervision of adults and without exceeding the recommended dosages. Reviews of the spray for children left by ENT doctors indicate the advisability of using this form of the drug to treat children after 6 years of age, while younger children (1-6 years old) are recommended to prescribe 0.05% drops.

Use of the drug Otrivin

Before administering the drug, you should thoroughly clean your nose. Drops of 0.05% are used on the recommendation of a doctor in infants and children under 6 years of age. 1-2 drops in each nasal passage 1-2 times a day. Apply every 8–10 hours, no more than 3 times a day in each nasal passage. Drops 0.1% - adults and children over 6 years of age. 2-3 drops in each nasal passage 3-4 times a day. Nasal spray dosed for adults and children over 6 years of age. 1 injection (0.14 mg xylometazoline) into each nasal passage 3-4 times a day. The duration of treatment depends on the course of the disease and should not exceed 10 consecutive days.

Otrivin during pregnancy and lactation

Drops and spray of this drug are not recommended for use by pregnant women . In case of urgent need to get rid of the manifestations of rhinitis , the attending physician may prescribe children's Otrivin during pregnancy (0.05%), but under strict control and in minimal dosages.

If there is a need to use Otrivin during breastfeeding , its administration is possible in minimal doses and only if the benefits of treatment clearly exceed the possible risks for the baby.

Otrivin Moisturizing formula, dosed nasal spray 0.1% 10ml

A country

Switzerland
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Xylometazoline

Description

Otrivin Moisturizing - spray is used for respiratory diseases with symptoms of rhinitis (runny nose)*: • Helps fight nasal congestion thanks to the active ingredient - xylometazoline.
• Moisturizing formula helps reduce symptoms of irritation and dryness of the nasal mucosa. • Relieves congestion in 2 minutes, maintaining the effect for up to 12 hours*. * Instructions for medical use, RU No. P N011649/04 dated 10.09.08

Compound

1 ml of the drug contains: Active ingredient: xylometazoline hydrochloride 1 mg. Excipients: sodium dihydrophosphate dihydrate 5 mg, sodium hydrophosphate dodecahydrate 1.7 mg, disodium edetate 0.5 mg, benzalkonium chloride 50% solution 0.1 mg (in terms of benzalkonium chloride 0.05 mg), sorbitol 70% 20 mg , hypromellose-4 thousand 5 mg, sodium chloride 4 mg, purified water up to 1 ml.

Product description

Transparent, colorless solution with virtually no odor

pharmachologic effect

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with an α-adrenomimetic effect, causing constriction of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasopharyngeal mucosa. Xylometazoline also reduces the accompanying hypersecretion of mucus and facilitates the drainage of nasal passages blocked by secretions, and thus improves nasal breathing during nasal congestion. Xylometazoline is well tolerated by patients with sensitive mucous membranes; its effect does not interfere with mucus secretion. Xylometazoline has a balanced pH value characteristic of the nasal cavity. The drug contains inactive components - sorbitol and hypromellose (methylhydroxypropylcellulose), which are humectants. Thus, the moisturizing formula helps reduce the symptoms of irritation and dryness of the nasal mucosa that occur with long-term use of xylometazoline. In therapeutic concentrations, the drug does not irritate the mucous membrane and does not cause hyperemia. The effect begins 2 minutes after application and lasts for 12 hours (for example, throughout the night). In vitro studies have shown that xylometazoline inhibits the infectivity of human rhinovirus, which causes the common cold. When applied topically in recommended dosages, it is practically not absorbed, plasma concentrations are below the detection limit.

Indications for use

Contraindications

Carefully

With caution: diabetes mellitus; pheochromocytoma; diseases of the cardiovascular system (including ischemic heart disease, angina pectoris); prostatic hyperplasia; with increased sensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

Use during pregnancy and lactation

Directions for use and doses

Intranasally. Adults and children over 12 years of age: 1 injection into each nasal passage 3 times a day. Should not be used more than 3 times a day. It is recommended to carry out the last application immediately before bedtime.

Side effect

Classification of the frequency of occurrence of adverse reactions: very often (≥ 10); often (≥1/100, Immune system disorders: Very rare: hypersensitivity reactions (angioedema, rash, itching). Nervous system disorders: Common: headache. Mental disorders: Rare: insomnia, depression (with long-term use in high doses).Visual disorders: Very rare: impaired clarity of visual perception. Cardiac disorders: Rare: palpitations. Very rare: tachycardia, arrhythmia. Vascular disorders: Rare: increased blood pressure. respiratory system, chest organs and mediastinum: Common: irritation and/or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the nasopharyngeal mucosa, drug-induced rhinitis Gastrointestinal disorders: Common: nausea Rare: vomiting. General disorders and disorders at the injection site: Common: burning at the application site.If any of the adverse reactions indicated in the instructions get worse, or you notice any other unwanted reactions not listed in the instructions, tell your doctor.

Overdose

Xylometazoline, when administered topically in an excessive dose or accidentally ingested, can cause severe dizziness, increased sweating, a sharp decrease in body temperature, headache, bradycardia, increased blood pressure, respiratory depression, coma and convulsions. Following an increase in blood pressure, a sharp decrease may be observed. Appropriate supportive measures should be taken if overdose is suspected, and in some cases immediate symptomatic treatment under medical supervision is indicated. These measures should include monitoring the patient for several hours. In case of severe poisoning with cardiac arrest, resuscitation efforts should last at least 1 hour.

Interaction with other drugs

special instructions

Release form

Dosed nasal spray, 0.1%. 10 ml of the drug in a white or transparent bottle made of high-density polyethylene, equipped with a pump dispenser with a tip and a protective cap made of polyethylene. The bottle along with instructions for use is placed in a cardboard pack. Secondary packaging is allowed to have a first-opening control.

Storage conditions

At a temperature not exceeding 30 C, out of the reach of children.

Best before date

3 years. Do not use after expiration date.

Reviews about Otrivin

In the case of using Otrivin drops and spray strictly according to indications and in recommended dosages, reviews of its effectiveness and safety are mostly positive. Adult patients using this drug note the speed and duration of its action and very rarely experience any side effects.

Reviews of Otrivin for children are most often left by parents who have personally experienced its effects on their children. Drops of this drug perfectly cope with the symptoms of a runny nose in children from the age of 1 year and in recommended doses do not lead to any side effects. The same parents note that Otrivin spray for children is more suitable for treating adolescents, where this dosage form is more appropriate for use than drops.

Otrivin price, where to buy

The average price of Otrivin spray 0.1% is 150 rubles, 0.05% is 160 rubles.

The average price of children's Otrivin in drops 0.05% is 150 rubles, drops for adults 0.1% is 160 rubles.

Online pharmacies in RussiaRussia
Online pharmacies in UkraineUkraine
Online pharmacies in KazakhstanKazakhstan

ZdravCity

Otrivin menthol nasal spray 0.1% 10 mlNovartis Consumer Health
RUB 189 order
Replaceable soft nozzles for nasal aspirator Otrivin Baby Comfort 10pcsGSK Consumer Healthcare S.A.
RUB 283 order
Otrivin Baby disposable replacement tips for nasal aspirator with absorbent filter 10 pcs.Novartis Consumer SA/STI Plastic
RUB 225 order
Otrivin Complex, dosed nasal spray with two active components, 0.1%, 10 mlGSK Consumer Healthcare S.A.
RUB 238 order
Otrivin Baby nasal aspirator with replaceable nozzles for removing mucus from the nose from birth 3 pcs. Novartis Consumer SA/STI Plastic
RUB 354 order

Pharmacy Dialogue

Otrivin Express nasal spray with menthol flavor 0.05% GSK Consumer Healthcare S.A.
RUB 271 order
Otrivin Baby disposable replacement tips N10STE Packaging Development
RUB 216 order
Otrivin Baby nasal aspirator with replaceable nozzles N3STE Packaging Development
RUR 366 order
Otrivin Moisturizing formula, nasal spray metered 0.1% 10mlNovartis Consumer Heaich
RUB 169 order
Otrivin Moisturizing formula, nasal spray metered 0.1% 10mlNovartis Consumer Heaich
RUB 159 order

Pharmacy24

Otrivin 0.1% 10 ml spray Novartis Consumer Health S.A., Switzerland
68 UAH.order
Otrivin Baby 5 ml N18 drops Novartis Consumer Health S.A., Switzerland
90 UAH order
Otrivin Baby No. 10 nozzle for nasal aspirator Novartis Consumer Health S.A., Switzerland
81 UAH order
Otrivin 0.05% 10 ml drops Novartis Consumer Health S.A., Switzerland
59 UAH order
Otrivin with menthol 0.1% 10 ml spray Novartis Consumer Health S.A., Switzerland
72 UAH order

PaniPharmacy

Otrivin Baby Nozzles for nasal aspirator No. 10 Switzerland, Novartis Consumer Health
93 UAH order
Otrivin liquid Otrivin drops 0.1% 10ml Switzerland, Novartis Consumer Health
68 UAH order
Otrivin liquid Otrivin drops 0.05% 10ml Switzerland, Novartis Consumer Health
68 UAH order
Otrivin Baby nasal aspirator Otrivin Baby Nasal aspirator complete with 3 nozzles Switzerland, Novartis Consumer Health
135 UAH order
Otrivin extra liquid Otrivin Extra spray name, dose. 10 ml bottle Switzerland, Novartis Consumer Health
85 UAH order

Otrivin Menthol nasal spray dosed 0.1% 10ml

A country

Switzerland
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Xylometazoline

Description

You feel Otrivin Menthol immediately!
* Otrivin Menthol with menthol and eucalyptus is used for respiratory diseases with symptoms of rhinitis (runny nose)*: • Helps fight nasal congestion thanks to the active substance - xylometazoline. • Due to the presence of menthol and eucalyptus in the composition, it has a cooling effect on the mucous membrane and gives a feeling of freshness. • Relieves congestion in 2 minutes, maintaining the effect for up to 12 hours**. * This refers to the effect of menthol. ** Instructions for medical use, RU No. P N011649/05 dated 09.11.2008

Compound

1 ml of the drug contains active ingredient: xylometazoline hydrochloride 1 mg. Excipients: sodium dihydrogen phosphate dihydrate 2 mg, sodium hydrogen phosphate dodecahydrate 2.8 mg, sodium chloride 5 mg, benzalkonium chloride, 50% solution 0.1 mg (in terms of benzalkonium chloride 0.05 mg), sorbitol 70% 14 mg, disodium edetate 0.5 mg, levomenthol (menthol) 0.3 mg, cineole (eucalyptol) 0.2 mg, macrogol glyceryl hydroxystearate 2.5 mg, purified water to 1 ml.

Product description

Colorless opalescent solution with a characteristic odor of menthol and eucalyptus.

pharmachologic effect

Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with an α-adrenomimetic effect; it causes constriction of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasopharyngeal mucosa. Xylometazoline also reduces the accompanying hypersecretion of mucus and facilitates the drainage of nasal passages blocked by secretions, and thus improves nasal breathing during nasal congestion. Otrivin is well tolerated by patients with sensitive mucous membranes; its effect does not interfere with mucus secretion. Otrivin has a balanced pH value characteristic of the nasal cavity. The menthol and eucalyptol contained in the preparation have a cooling effect on the nasal mucosa, giving a feeling of freshness. In therapeutic concentrations, the drug does not irritate the mucous membrane and does not cause hyperemia. The effect occurs 2 minutes after application and lasts for 12 hours (for example, throughout the night). In vitro studies have shown that xylometazoline inhibits the infectivity of human rhinovirus, which causes the common cold. When applied topically in recommended dosages, it is practically not absorbed, plasma concentrations are below the detection limit.

Indications for use

Contraindications

Carefully

With caution: diabetes mellitus; pheochromocytoma; diseases of the cardiovascular system; prostatic hyperplasia; with increased sensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

Use during pregnancy and lactation

Directions for use and doses

Intranasally. Adults and children over 12 years of age: 1 spray into each nasal passage 3 times a day. Should not be used more than 3 times a day. It is recommended to carry out the last application immediately before bedtime.

Side effect

Classification of the frequency of occurrence of adverse reactions: very often (≥ 10); often (≥1/100, from the immune system: very rarely: hypersensitivity reactions, angioedema, rash, itching). From the nervous system: often: headache. Rarely: insomnia, depression (with long-term use in high doses). From the senses: Very rarely: impaired clarity of visual perception. From the cardiovascular system: Rarely: palpitations, increased blood pressure. Very rare: tachycardia, arrhythmia. From the respiratory system: Often: irritation and/or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the nasopharyngeal mucosa. From the digestive system: Often: nausea. Rarely: vomiting. Local reactions: Often: burning at the site of application. If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Xylometazoline, when administered topically in an excessive dose or accidentally ingested, can cause severe dizziness, increased sweating, a sharp decrease in body temperature, headache, bradycardia, increased blood pressure, respiratory depression, coma and convulsions. Following an increase in blood pressure, a sharp decrease may be observed. Appropriate supportive measures should be taken if overdose is suspected, and in some cases immediate symptomatic treatment under medical supervision is indicated. These measures should include monitoring the patient for several hours. In case of severe poisoning with cardiac arrest, resuscitation efforts should last at least 1 hour.

Interaction with other drugs

special instructions

Release form

Dosed nasal spray [with menthol and eucalyptus] 0.1%. 10 ml of the drug in a white or transparent bottle made of high-density polyethylene, equipped with a pump dispenser with a tip and a protective cap made of polyethylene. The bottle along with instructions for use is placed in a cardboard pack. Secondary packaging is allowed to have a first-opening control.

Storage conditions

At a temperature not exceeding 25 C, out of the reach of children.

Best before date

2.5 years. Do not use after expiration date.